Moving Toward Continuous Therapy in Multiple Myeloma.

ABSTRACT: The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy currently represents the standard approach for myeloma patients both at diagnosis and at relapse. In younger patients, long-term maintenance after autologous transplantation significantly improved progression-free survival and overall survival compared to observation. Also in transplant-ineligible patients, continuous treatment with combinations of newer agents and maintenance treatment following a more intense induction phase proved to be superior as compared to fixed-duration therapy. Maintenance and continuous therapy at diagnosis have shown to

SUBMITTER: Bonello F 

PROVIDER: S-EPMC8432368 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature